세계의 조직학 및 세포학 시장 규모, 점유율, 동향 분석 보고서 : 검사 유형별, 제품별, 용도별, 지역별, 부문 예측(2025-2030년)

Histology And Cytology Market Size, Share & Trends Analysis Report By Type of Examination (Histology, Cytology), By Product (Instruments & Analysis Software System, Consumables & Reagents), By Application, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

조직학 및 세포학 시장 성장 및 동향 :

Grand View Research의 최신 보고서에 따르면, 세계 조직학 및 세포학 시장 규모는 2030년까지 494억 8,000만 달러에 달할 것으로 예측됩니다.

이 시장은 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 15.31%를 보일 것으로 예측됩니다. 시장 성장 요인으로는 질병 조기 발견에 대한 수요 증가, 병리 검사실의 표준화 진행, 면역조직화학의 도입과 현미경 검사 혁신 등을 꼽을 수 있습니다.

각 조직은 세포병리학의 세계 표준화를 위한 공동연구에 집중하고 있으며, 이는 시장 성장에 긍정적인 영향을 미치고 있습니다. 예를 들어, 2022년 11월, 케냐에 새로운 IARC GICR 협력 센터가 설립되어 교육을 통해 사하라 이남 아프리카의 암 등록을 촉진하기 위해 설립되었습니다. 이 협력 센터는 지역 교육 과정과 CanReg5 소프트웨어의 구현 및 개발에 중점을 두고 있습니다.

또한, 각 기업들은 세포 진단을 위한 새로운 자동화된 기기를 출시하고 있으며, 이는 조직 및 세포 진단 산업의 성장에 더욱 기여하고 있습니다. 예를 들어, 2021년 1월 F. Hoffmann-La Roche Ltd는 uPath HER2(4B5) 이미지 분석과 uPath HER2Dual ISH 이미지 분석의 두 가지 자동 디지털 병리 알고리즘을 출시하였습니다.

코로나19는 인공지능(AI)과 디지털화 솔루션의 통합을 통해 기존의 병리학적 워크플로우를 변화시키는 계기가 되었습니다. 이러한 도구들은 팬데믹 기간 동안 병리학적 사례의 원격 검토를 지원했고, 지금도 계속 지원하고 있습니다. 그 결과, 환자 치료 지연을 방지할 수 있으며, 코로나19 이후 디지털 병리 솔루션의 채택이 증가하고 있다고 기업들은 보고하고 있습니다.

조직학 및 세포학 시장 보고서 하이라이트

• 세포진단 분야는 2024년 가장 큰 매출 점유율을 차지했으며, 세포진단 시스템의 발전에 따른 계산 분석 도구의 통합으로 인해 예측 기간 동안 이러한 추세가 지속될 것으로 예측됩니다.
• 소모품 및 시약 부문은 조직학 및 세포학 산업을 지배하고 있으며, 이는 소모품 시장에서 사업을 운영하는 기업의 포트폴리오가 확대되고 있기 때문입니다. 기기 및 분석 소프트웨어 시스템 부문은 자동 조직 검사 장비에 대한 수요가 급증함에 따라 2025년부터 2030년까지 상당한 CAGR로 성장할 것으로 예측됩니다.
• 신약 개발 및 약물 설계 부문은 2024년 가장 높은 매출 점유율을 차지했으며, 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예측됩니다.
• 북미는 암의 확산, 주요 기업의 존재, 발달된 의료 인프라로 인해 2024년 가장 높은 수익을 창출하는 지역으로 부상했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 조직학 및 세포학 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 조직학 및 세포학 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석
  • 가격 분석

제4장 조직학 및 세포학 시장 : 검사 유형 추정 및 동향 분석

• 세계의 조직학 및 세포학 시장 : 대시보드
• 세계의 조직학 및 세포학 시장 : 변동 분석
• 세계의 조직학 및 세포학 시장 : 매출
• 조직학
  • 기법별
• 세포학
  • 기법별
  • 용도별

제5장 조직학 및 세포학 시장 : 제품 추정 및 동향 분석

• 세계의 조직학 및 세포학 시장 : 제품 대시보드
• 세계의 조직학 및 세포학 시장 : 제품 변동 분석
• 세계의 조직학 및 세포학 시장 : 제품별 매출
  • 기기 및 분석 소프트웨어 시스템
  • 소모품 및 시약

제6장 조직학 및 세포학 시장 : 용도 추정 및 동향 분석

• 세계의 조직학 및 세포학 시장 : 용도 대시보드
• 세계의 조직학 및 세포학 시장 : 용도 변동 분석
• 세계의 조직학 및 세포학 시장 : 용도별 매출
• Drug Discovery 및 설계
• 임상 진단
  • POC(Point of Care)
  • 비PoC
• 연구

제7장 조직학 및 세포학 시장 : 검사 유형, 제품, 용도 및 조사 방법별 지역 추정 및 동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년까지 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • 주요 유통업체 및 채널 파트너 리스트
  • Key customers
  • Key company market share analysis, 2024
  • Hologic, Inc.
  • Abbott
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Danaher
  • Sysmex Corporation
  • Trivitron Healthcare
  • Koninklijke Philips NV

LSH

영문 목차

영문목차

Histology And Cytology Market Growth & Trends:

The global histology and cytology market size is anticipated to reach USD 49.48 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 15.31% from 2025 to 2030. The factors contributing to market growth include increasing demand for early detection of diseases, increased standardization of pathology laboratories, and implementation of immunohistochemistry and innovation in microscopy.

Organizations are focusing on collaborations for the standardization of cytopathology globally, positively impacting market growth. For instance, in November 2022, a novel IARC GICR collaboration center was established in Kenya to advance cancer registration in sub-Saharan Africa via training. The collaborating center focuses on regional training courses and the implementation & development of the CanReg5 software.

Moreover, companies are launching novel and automated instruments for cytology which can be further attributed to the histology and cytology industry growth. For instance, in January 2021, F. Hoffmann-La Roche Ltd launched uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis-two automated digital pathology algorithms that offer rapid & accurate patient diagnoses in breast cancer.

COVID-19 became a catalyst for changing traditional pathology workflows with the integration of artificial intelligence (AI) and digitalization solutions. During the pandemic, these tools helped and continue to assist in the remote reviewing of pathological cases. Thus, preventing delays in patient care. Companies have reported increasing adoption of digital pathology solutions post-COVID-19.

Histology And Cytology Market Report Highlights:

• The cytology segment accounted for the largest revenue share in 2024 and is expected to continue the trend in the forecast period owing to the integration of computational analytical tools for advancing cytology systems
• The consumables and reagents segment dominated the histology and cytology industry, attributed to the expanding portfolios of the entities operating in the consumable market. The instruments and analysis software system segment is expected to grow at a substantial CAGR from 2025 to 2030, attributed to the steep increase in the demand for automated histology instruments
• Drug discovery & designing segment accounted for the highest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period, owing to the growing importance of cytopathology in disease understanding, further aimed at rapid drug development
• North America emerged as the highest revenue-generating region in 2024, owing to the prevalence of cancer, the presence of key players, and the developed healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type of Examination
  • 1.2.2. Product
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type of examination outlook
  • 2.2.2. Product outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Histology and Cytology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of cancer
    • 3.2.1.2. Technological developments
    • 3.2.1.3. Increase in awareness programs for cervical cancer screening
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Low sensitivity of cytology tests
    • 3.2.2.2. Conditions required for specimens and problem of mislabeled specimens
• 3.3. Histology and cytology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Histology and cytology Market: Type of Examination Estimates & Trend Analysis

• 4.1. Global Histology and Cytology Market: Type Of Examination Dashboard
• 4.2. Global Histology and Cytology Market: Type of Examination Movement Analysis
• 4.3. Global Histology and Cytology Market by Type of Examination, Revenue
• 4.4. Histology
  • 4.4.1. Histology market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. By Technique
    • 4.4.2.1. Microscopy
      • 4.4.2.1.1. Microscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Immunohistochemistry
      • 4.4.2.2.1. Immunohistochemistry market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Molecular pathology
      • 4.4.2.3.1. Molecular pathology market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.4. Cryostat & Microtomy
      • 4.4.2.4.1. Cryostat & Microtomy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Cytology
    • 4.4.3.1. Cytology market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. By Technique
    • 4.4.4.1. Microscopy
      • 4.4.4.1.1. Microscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.2. Immunohistochemistry
      • 4.4.4.2.1. Immunohistochemistry market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.3. Molecular pathology
      • 4.4.4.3.1. Molecular pathology market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.4. Cryostat & Microtomy
      • 4.4.4.4.1. Cryostat & Microtomy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. By Application
    • 4.4.5.1. Breast Cancer
      • 4.4.5.1.1. Breast Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.2. Cervical Cancer
      • 4.4.5.2.1. Cervical Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.3. Bladder Cancer
      • 4.4.5.3.1. Bladder Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.4. Lung Cancer
      • 4.4.5.4.1. Lung Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.5. Other Cancers
      • 4.4.5.5.1. Other Cancer market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Histology and cytology Market: Product Estimates & Trend Analysis

• 5.1. Global Histology and Cytology Market: Product Dashboard
• 5.2. Global Histology and Cytology Market: Product Movement Analysis
• 5.3. Global Histology and Cytology Market by Product, Revenue
  • 5.3.1. Instruments and Analysis Software System
  • 5.3.2. Instruments and analysis software system market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. Consumable and Reagents
  • 5.3.4. Consumable and reagents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Histology and cytology Market: Application Estimates & Trend Analysis

• 6.1. Global Histology and Cytology Market: Application Dashboard
• 6.2. Global Histology and Cytology Market: Application Movement Analysis
• 6.3. Global Histology and Cytology Market by Application, Revenue
• 6.4. Drug Discovery & Designing
  • 6.4.1. Drug discovery & designing market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Diagnostics
  • 6.5.1. Clinical diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Point-of-Care (PoC)
    • 6.5.2.1. Point-of-Care (PoC) market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Non-PoC
    • 6.5.3.1. Non-PoC market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Research
  • 6.6.1. Research market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Histology and cytology Market: Regional Estimates & Trend Analysis by Type of Examination, Product, Application and Methodology

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Hologic, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Abbott
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Becton, Dickinson and Company
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. F. Hoffmann-La Roche Ltd
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Merck KGaA
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Thermo Fisher Scientific, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Danaher
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Sysmex Corporation
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Trivitron Healthcare
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Koninklijke Philips N.V.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives

관련자료